MUSTANG BIO, INC.
MBIO · XNASCIK 1680048fmd_1WW2A9ST1FSNV339PQ3XDQRAD4Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Sep 30, 2026, 46 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 2 | 0 | 2 | 30 | 37 | 50 | 62 | 41 | 8 | – |
| Total operating expenses | 11 | 32 | 31 | 46 | 57 | 67 | 76 | 49 | 16 | 2 |
| Operating income | (11) | (32) | (31) | (46) | (57) | (67) | (76) | (49) | (16) | (2) |
| Interest expense | 1 | 0 | 0 | 2 | 4 | 0 | 3 | 4 | 0 | – |
| Other non-operating income (expense) | (1) | 0 | 1 | (1) | (3) | 0 | (1) | (2) | 0 | 1 |
| Income before taxes | – | – | – | – | – | – | – | – | (16) | (2) |
| Income tax expense | – | – | – | – | – | – | – | – | – | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | – | (2) |
| Net income | (13) | (31) | (31) | (46) | (60) | (66) | (78) | (52) | (16) | (2) |